Nonalcoholic Fatty Liver Disease and the Gut Microbiota: Exploring the Connection

Edward C. Oldfield1, Ray Z. Dong1 and David A. Johnson2*

1Eastern Virginia Medical School, Norfolk VA, USA
2Division of Gastroenterology, Eastern Virginia Medical School, Norfolk VA, USA

Corresponding author: David A Johnson, Department of Internal Medicine Chief, Eastern Virginia Medical School, Norfolk VA, USA, Tel: 7576416685; Fax: 7574405713; E-mail: dajevms@aol.com

Received date: Nov 17 2014, Accepted date: Dec 19 2014, Published date: Dec 23 2014

Copyright: © 2014 Oldfield EC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium provided the original author and source are credited.

Abstract

As the gut microbiota becomes to be implicated in an increasing number of disease processes, a plethora of new literature surrounding its complexity and role in the maintenance of intestinal homeostasis has become available. Nonalcoholic fatty liver disease (NAFLD) has become the most common nonviral liver disease worldwide and a number of predisposing risk factors for NAFLD have been identified, including obesity and insulin resistance. Recent evidence supports a role for the gut microbiota in the pathogenesis of these risk factors and NAFLD itself. Additionally changes in the gut microbiota can lead to activation of immune responses that have the potential to promote progression of NAFLD to the more severe nonalcoholic steatohepatitis (NASH). Furthermore, the gut microbiota may serve as a potential target for therapeutic options to treat NAFLD. This review seeks to explain the role of the gut microbiota in the pathogenesis of NAFLD and its risk factors, while also discussing potential future treatment options directed at correcting imbalances with in the gut microbiota.

Keywords: Non-alcoholic fatty liver disease; Microbiota; Insulin resistance; Metabolic syndrome; Steatohepatitis; Inflammosomes

Introduction

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver disease defined as the presence of lipids in >5% of hepatocytes or a lipid content >5% of liver weight in the absence of significant alcohol intake (>20g of alcohol/day), hepatic viral infections or the use of potentially hepatotoxic medications [1,2]. Worldwide NAFLD has become the most common nonviral liver disease affecting over one billion individuals with an estimated prevalence of 6-30% in the general population in part due to the increasing incidence of obesity and as well due to related other metabolic risk factors [1-4]. Currently NAFLD related chronic liver disease is the 3rd leading indication for liver transplantation in the U.S. and is expected to be the leading cause in 2020 [2]. Steatosis in NAFLD can progress to non-alcoholic steatohepatitis (NASH) with fibrosis. This may further be subject to progressive changes in inflammation and fibrosis that can lead to liver cirrhosis, end stage liver disease and also an increased risk for hepatocellular carcinoma (HCC) [2,4]. The initial diagnosis of NAFLD is often suggested incidentally during abdominal ultrasonography as most patients with NAFLD are asymptomatic [3]. Predisposing factors for the development of NAFLD include those of the metabolic syndrome: abdominal obesity, hypertriglyceridemia, low HDL, hypertension and insulin resistance.

With >1014 different microorganisms the gut microbiota is considered as a major metabolic internal organ intimately involved in molecular “cross-talk with the intestinal epithelium and affecting the intestinal barrier function [5,6]. Recent attention has focused around the gut microbiota not only as part of the disease process but also as a potential target for treatment. The focus of this article is to explore the link between the human gut microbiota and NAFLD as disruption of the gut microbiota may predispose patients to developing NAFLD.

Beginning with a review of the relevant pathophysiology this article will address the role of the liver and gut microbiota in both metabolic and immune regulation. Further discussion of specific alterations in the gut microbiota in direct relation to each of the major risk factors for NAFLD will follow. Lastly a review of the therapeutic options functioning to modify the gut microbiota will be addressed.

Pathophysiology

In order to understand the pathogenesis of NAFLD it is essential to have a basic understanding of hepatic function and its relationship to the predisposing risk factors for NAFLD. The liver is the main warehouse for various lipids including triglycerides free fatty acids (FFA), diacylglycerol, free cholesterol, cholesterol esters, ceramides and phospholipids. The hallmark pathogenesis of NAFLD is the presence of ectopic fat within hepatocytes which results from an imbalance in the levels of lipogenesis and lipolysis [2]. Triglycerides are synthesized from FFAs that accumulate that within the liver; therefore the concentration of FFAs functions as a regulator of lipogenesis. Importantly the hepatic uptake of FFAs is unregulated and is directly proportional to the level of nonesterified fatty acids (NEFAs) which accounts for 60% of FFAs accumulation within the liver primarily from lipolysis in adipose tissue [2]. Other sources of FFAs include de novo lipogenesis (25%) and dietary fatty acids (15%) in the form of chylomicrons lipoproteins [2]. After FFAs are taken up by the liver they have three potential fates: oxidation within mitochondria VLDL (very low-density lipoprotein) assembly and export or triglyceride synthesis and storage as lipid droplets (Figure 1). Over time an abundance of triglycerides accumulates and leads to increased hepatic storage of lipid droplets promoting the progression towards NAFLD [2].
Many of the risk factors for NAFLD alter the balance of these three pathways. For instance in patients with insulin resistance there is a decreased ability of insulin to suppress adipose tissue lipolysis which leads to increased hepatic uptake of FFA [2]. Also in patients with NAFLD de novo lipogenesis during fasting state increases by 3 fold compared to those with a lean liver [2]. Furthermore excess insulin induces sterol response element-binding protein-1c (SREBP-1c) and peroxisome proliferator-activated receptor-γ (PPAR-γ) to promote the expression of several lipogenic genes generating more lipids and contributing a greater burden to the liver [7]. Lastly dietary FAs are positively correlated with a high fat diet in which >30% of total energy requirement is provided as fat [8].

Another critical factor in the pathogenesis of NAFLD is the interactions between the specific risk factors for NAFLD. The result is a complex pathway that leads to a cyclic pattern of inflammation and injury. To start high fat diet and obesity lead to increased peripheral adipose tissue which initiates insulin resistance (IR). The excessive accumulation of fat in adipocytes promotes an increase in oxidative stress and low grade inflammatory state through the release of inflammatory markers including interleukin-6 (IL-6) and monocyte chemotactic protein 1 (MCP-1) [9]. Subsequently the activation of macrophages and lymphocytes promotes further release of proinflammatory cytokines associated with insulin resistance namely tumor necrosis factor-α (TNF-α) and interferon-γ (INF-γ), promoting a continuation of the cycle [10].

Progression from NAFLD to NASH occurs in roughly 20% of cases and is characterized by the hallmark lobular chronic inflammatory infiltrate without any secondary causes of hepatic fat accumulation e.g. significant alcohol consumption use of steatogenic medication or hereditary disorders [2,4,11]. Injury and inflammation are thought to be the major factors that lead NAFLD progression to NASH and fibrogenesis [2]. One potential explanation for the progression to NASH is lipotoxicity a process in which increased oxidative stress secondary to accumulation of lipids overwhelms the hepatic function of metabolism. Lipotoxicity also leads to impaired autophagy causing cell damage and cell death and induces an inflammatory and wound healing response that can lead to fibrogenesis [2]. Additionally a variety of bacterial products can activate various immune responses further promoting inflammation through the expression of proinflammatory cytokines [12]. These immune responses will be analyzed and discussed more thoroughly in a later section.

**Microbiota in NAFLD risk factors**

Although a number of genetic and environmental factors have been linked in the pathogenesis of NAFLD, obesity, insulin resistance and immune responses are the more dominant risk [2,12]. First obesity in particular central obesity is highly predictive of hepatic steatosis and disease progression. In overweight (BMI >25) patients the prevalence of steatosis is at least two times more frequent than in lean subjects directly proportional to elevated body mass index (BMI) [2]. In extreme obesity (BMI >40) most patients have NAFLD steatosis and more than one third have NASH [13]. Secondly insulin resistance plays a huge role in developing NAFLD evidenced by a 5-9 fold increased risk for NAFLD in patients with type 2 diabetes mellitus (T2DM) as compared to the general population; further two thirds of these patients with T2DM develop NAFLD [14,15]. Third the immune system regulates inflammatory responses to a variety of bacterial products that can be altered in NAFLD. This section seeks to more closely explore the relationship between each of these risk factors and their association with changes in the gut microbiota.

**Obesity**

The gut microbiota has been recently linked to the pathogenesis of obesity through a number of pathways [16]. In particular modification of appetite and alteration of de novo lipogenesis appear to be essential mechanisms by which the gut microbiota maximizes hepatic triglyceride content [5,11]. Evidence for these mechanisms comes from animal studies where germ-free (GF) animals born and raised in a sterile environment lacking gut flora were resistant to the development of obesity when fed a high-fat high-sugar diet; however after introducing gut flora to these GF mice there was an increase in energy harvested from the diet with increased intestinal monosaccharide uptake. Additionally these mice had increased weight and body fat content with increased hepatic lipogenesis and fat deposition which eventually led to the development of insulin resistance [11,16,17].

Within the gut microbiota two predominate species of bacteria *Firmicutes* and *Bacteroidetes* have been influential in the development of metabolic syndrome [11]. The balance of these two bacteria is dysregulated in patients with metabolic syndrome and obesity evidenced by multiple studies showing an excess of *Firmicutes* and reduction of *Bacteroidetes* compared to lean counterparts [11,16,18]. In these studies more *Firmicutes* resulted in increased fermentation end products such as short-chain fatty acids (SCFAs). These SCFAs in turn play a major role in appetite regulation by not only diffusing passively into circulation but also by acting as signaling molecules [11,19]. Certain SCFAs such as propionate and acetate can bind to G protein-coupled receptors (GPCRs) to induce release of peptide YY (PYY) [20]. PYY is an enteroendocrine cell-derived hormone that normally inhibits gut motility and increases nutrient absorption so abundant SCFAs increase calorie absorption by stimulating PYY leading to obesity. Furthermore excess SCFAs will also be converted into triglycerides in the liver which can cause hepatic steatosis [19]. These studies give us insight that further therapeutic approaches to obesity could target this specific gut flora [21].
These “typical” changes in the obese human gut microbiota however have not been found by all investigators. Schwierz et al. reported lower ratios of *Firmicutes* to *Bacteroidetes* in obese human adults compared to lean controls [22]; however significant diet-dependent reductions in a group of butyrate-producing *Firmicutes* were found [23]. In 2011, Arumugam et al. studied the phylogenetic composition of 39 fecal samples from individuals representing 6 nationalities and found that there was no correlation between body mass index and the *Firmicutes/Bacteroidetes* ratio [24]. On the other hand the identification of three metagenomic-derived functional biomarkers that strongly correlate with body mass index (BMI), suggests that differences at the phylum level are probably less important than metagenomic-based functional aspects [20,24].

Besides the gut flora changes and metagenomic biomarkers there are also a few studies targeting how the gut microbiota puts patients at risk for obesity on a molecular level. Bäckhead et al. showed that fasting-induced adipocyte factor (*Fiaf*) a member of the angioptin-like family of proteins is suppressed in the intestinal epithelium by the microbiota [25]. This suppression leads to increased lipoprotein lipase (LPL), a key regulator of fatty acids which results in increased cellular uptake of fatty acids and adipocyte triglyceride accumulation. Further investigation revealed that when the gut was colonized with *Bacteroides thetaiotaomicron* and *Methanobrevibacter smithii* there was a significant increase in suppression of *Fiaf* which leads to obesity [26].

More than just the bacteria living in the gut microbiota may influence energy homeostasis. Zhang et al. reported an association between methanogenic *Archaea* (microorganisms which produce methane as a byproduct during anoxic conditions) and obesity [27]. Increased levels of *Archaea*-derived gene fragments were detected in obese mice compared to their lean relatives suggesting that methanogens in the gut may play a pivotal role in fermentation and ultimately lead to production of SCFAs with the net result being energy harvest and weight gain [28,29]. A proposed explanation is that methanogens remove fermentation intermediate such as H2 (hydrogen gas) or formate relieving thermodynamic limitations and allowing greater production of SCFAs that are available to be absorbed across the intestinal epithelium while at the same time extracting more energy from indigestible polysaccharides [27]. The study concluded that interspecies H2 transfer between bacterial and archaeal species affects energy uptake in humans and puts patients at risk for obesity [27]. SCFAs also regulate gut hormones via free fatty acid receptors 2 (FFAR2) and 3 (FFAR3) which promote energy storage by stimulating adipogenesis and inhibiting lipolysis. This decrease in energy expenditure ultimately leads to obesity and other metabolic diseases [28–30].

**Bottom line**

Obesity is clearly a strong risk factor in the pathogenesis of NAFLD with a prevalence twice that of lean comparators. High fat diets increase the accumulation of FFAs within the liver ultimately leading to NAFLD. The gut microbiota has been shown to be intimately involved in this pathway as a characteristic increase in *Firmicutes* and reduction in *Bacteroidetes* have been widely documented. This alteration in the normal ratio affects the regulation of gut hormones such as PYY and also number of regulatory factors for lipolysis and lipogenesis including *Fiaf*, LPL, FFAR2 and FFAR3. Continued investigation into the alterations in the gut microbiota in obesity may help to further our understanding NAFLD and explain key differences in environmental versus genetic factors.

**Insulin Resistance**

Environmental factors and host genetics play major roles in establishing and maintaining gut microbiota while in turn interacting to sustain the homeostasis of gut weight control and insulin sensitivity [31,32]. Previously discussed inflammatory mediators such as TNF-alpha, IL-6, inducible nitric oxide and nuclear factor (NF-κB) have already been shown to be increased when the gut microbiota is altered or disrupted. Here we will discuss the mechanisms behind which changes in gut microbiota may promote insulin resistance.

Certain inflammatory mediators involved in the development of insulin resistance are controlled by Toll-like receptor 4 (TLR4) activated by lipopolysaccharide (LPS) from gram negative bacteria highlighting a link between insulin resistance and liver inflammation through several pathways responsible for the regulation of hepatocyte apoptosis and insulin signaling [16,33]. Important functions of TLR4 in relation to insulin resistance are the upregulation of both c-Jun NH2-terminal kinase (JNK) and 1xβ kinase complex (1KKβ) and also decreased phosphorylation of insulin receptor substrate (IRS)-1. The IRS-1 is needed for glucose transport in muscle and adipose tissue, glycogen synthesis in muscle and liver and lipogenesis in adipose tissue while [JKN and 1KKβ disrupt appropriate insulin signaling leading to insulin resistance [34,35]. The LPS also induces insulin resistance by promoting the expression of NF-κB and activation of the MAPK pathway in adipocytes [34,36]. New evidence also suggests LPS can promote the expression of iNOS (inducible nitric oxide synthase) by hampering LPL activity and increasing lipolysis ultimately worsening insulin resistance by increasing levels of circulating fatty acids [34,37].

Other bacterial factors that play a role in the development of insulin resistance could be nucleotide oligomerization domain (NOD)-1 and -2 proteins. These NOD proteins are intracellular pattern recognition receptors that can sense bacterial cell wall peptidoglycan (PGN) moieties which then induce stress and inflammation pathways [34,38]. NOD-1 detects PGN found in gram-negative bacteria whereas NOD-2 detects gram-positive bacteria [38]. Activation of NOD-1 in adipocytes leads to impaired insulin signaling and decreased insulin-stimulated glucose uptake [39]. While activated NOD-2 leads to muscle cell-autonomous insulin resistance [40].

Adenosine monophosphate-activated protein kinase (AMPK) is an enzyme which plays an active role in energy homeostasis. It is activated to offset the energy deprived state by stimulating fatty acid oxidation, ketogenesis and glucose uptake insulin secretion while inhibiting cholesterol synthesis lipogenesis and triglyceride synthesis [28,41]. Bäckhead et al. demonstrated that the expression of AMPK is suppressed by microbiota thereby predisposing the host to obesity and insulin resistance [26].

A few animal studies have also investigated the link between insulin resistance and the gut microbiota in particular how the translocation of gut microorganisms and their byproducts into portal and systemic circulation may cause hepatic inflammation and insulin resistance. It has been shown that mice on a HFD have greater accumulation of bacteria close to the mucosa of the intestinal lumen, which facilitates their translocation through the epithelium [42]. This high level of bacteria at the mesenteric adipose tissue (MAT) triggers inflammatory markers through LPS released by bacteria, eventually leading to
systemic inflammation and insulin resistance [42]. Interestingly mice
given one month of probiotics showed complete normalization of
insulin sensitivity, inflammation and fasting hyperinsulinemia further
supporting the gut microbiota as a potential target in insulin resistant
diabetic patients [42]. Another study done by Caricilli et al looked at
gut microbiota on a molecular level in association with insulin resistance [31]. Their results showed that in TLR2 knockout mice
conventionalization (as opposed to “germ-free” condition) results in
a phenotype reminiscent of metabolic syndrome, characterized by
different gut flora, with a 3-fold increase in *Firmicutes* and a slight
increase in *Bacteroidetes* compared with control; further, antibiotics
were able to reverse these adverse outcomes [31]. Once again, LPS
absorption, subclinical inflammation, insulin resistance and glucose
intolerance are all sequelae of these changes in microbiota.

**Bottom-line**

As compared to obesity, which primarily predisposes to NAFLD
on the basis of increased FFA within the liver, insulin resistance
appears to affect a wider variety of biochemical pathways involved in
the pathogenesis of NAFLD. Insulin resistance is closely linked to
inflammatory mediators and regulation of signaling cascades that
affect glucose transport in muscle and adipose tissue, glycogen
synthesis and lipogenesis. In these respect alterations in the gut
microbiota that affect activation of immune response can potentially
modify insulin resistance.

**Cellular Immunity and Inflammation**

While obesity and metabolic syndrome are undoubtedly the most
important risk factors for the development of NAFLD, the relationship
between the immune system and the gut microbiota appears to have a
more essential role in the inflammatory processes that drive the
change from NAFLD to NASH. The pathogenesis of NASH was
originally described as a “two-hit” hypothesis in which the “first hit,”
hepatic steatosis, acts to sensitize the hepatocytes for the “second hit,”
either genetic factors, oxidative stress, gut-derived endotoxins, or
inflammatory cytokines [43]. More recently, new evidence has
emerged suggesting that inflammation may be able to proceed
steatosis in some cases, suggesting that multiple parallel hits may occur
to initiate the progression to NASH [44]. While there a number of
factors involved in this complex pathway leading to NASH, this review
will focus on the role of the innate immune system and its relationship
to endotoxin and gut derived signals.

During the progression from NAFLD to NASH, injured cells and
necrotic tissues release molecules such as damage-associated
molecular patterns (DAMPs), which trigger inflammation through the
binding of several receptors. These receptors can be specific or shared
with pathogen-associated molecular patterns (PAMPs) that recognize
molecular patterns associated with microbial pathogens or cellular
stress. The essential foundation for the relationship between the
immune system and the gut microbiota is the recognition of these
PAMPs and DAMPs via Toll-like receptors (TLRs) or Nod-like
receptors (NLRs). Both TLRs (located on the cell surface or within
endosomes) and NLRs (located within the host cytosol) function to
recognize microbial products and activate signaling pathways of both
innate and adaptive immune responses [45]. In order to understand
the impact that gut microbiota alterations can have on the immune
system, it is important to more closely analyze the major receptors
in each of the families.

**Toll-like Receptors**

The TLRs often represent a first line of defense based on their cell
surface location and recognition of a variety of microbial signals. In
the liver, TLRs are an essential piece of immunity as the portal system
has the potential to be a significant source of microbial products and
any disruption in the balance can lead to excess inflammation within
the liver. The four main TLRs involved in NAFLD and NASH is: TLR2
recognizing peptidoglycan and lipoteichoic acid both components of
gram-positive bacterial cell walls; TLR4 recognizing
lipopolysaccharide (LPS) from gram-negative bacteria; TLR5 a
receptor for bacterial flagellin; and TLR9 recognizing unmethylated
CpG motifs in bacterial DNA [12].

To date a number of studies performed in animal models have helped
to explain the significance of these receptors in the development of
NAFLD. Evidence for the relationship between the gut microbiota and
TLRs is multifocal although key factors are alterations in the
microbiota along with a related increased intestinal
permeability. These factors have been demonstrated in rodent models
through a variety of diets including high-fat diet (HFD), methionine-
choline deficient diet (MCD), and choline–deficient amino acid
defined diet (CDDA) [12]. For example it has been shown that rodents
placed on a high-fat diet (HFD) have increased inflammation through
the induction of TLR4 which leads to increased intestinal permeability
and increased endotoxin levels further accelerating obesity;
importantly, this effect was not reproducible with the HFD in TLR4
deficient mice [46]. Additionally, a number of other studies have shown
that TLR4 mutant mice are resistant to the development of
NAFLD [47-49]. Similar models using a methionine choline-deficient
(MCD) diet were able to induce NASH evidenced by increased liver
triglyceride accumulation, lipid peroxidation, serum ALT, TNF-α,
NADPH and markers of liver fibrosis [48]. When knockout mice
deficient for TLR4 and its co-receptor MD-2 (myeloid differentiation
factor) were also placed on the MCD diet however, these increases
were attenuated. The authors of this study suggest that these results
demonstrate a role for LPS recognition via TLR4 and MD-2 for
inducing liver steatosis and fibrosis in a NASH model in mice [48].
This conclusion is supported by several mouse models in which LPS
injections in NAFLD mice were able to further promote liver injury
through increased levels of proinflammatory cytokines [50,51]. This
represents an important finding, as levels of LPS in humans are also
elevated in those with metabolic syndrome and NAFLD [12].

Among patients with biopsy-proved NAFLD, increased small
intestine bacterial overgrowth has been associated with disrupted
intercellular tight junctions, leading to increased intestinal
permeability and delivery of LPS to the portal system [52]. In patients
with type 2 diabetes mellitus, circulating levels of LPS were shown to
be 76% higher than in matched controls and further associated with
significant increases in TNF-α and IL-6 [53]. Another mechanism by
which TLR increases inflammation is through the potent activation
of Kupffer cells within the liver [47]. This activation of Kupffer cells
can induce a pathological effect by inducing reactive oxygen species
(ROS)-dependent activation of X-box binding protein-1 (XBP-1),
which is a key transcription factor mediating unfolded protein
response in ER (endoplasmic reticulum) stress [54]. Additionally, in
this rodent model of NASH, Kupffer cell depletion led to an
abrogation of the high-fat, high-cholesterol diet induced TLR4
expression; this suggests that Kupffer cells are a major source of pro
inflammatory mediators through an increased expression of TLR4
[54].
Toll like Receptor 9, which recognizes unmethylated CpG motifs in bacterial DNA has also been shown to play an important role in the progression to NASH. Using a CDAA diet induced NASH model, researchers were able to show that TLR9 signaling induced IL-1β production leading to steatosis, inflammation and fibrosis which was also associated with insulin resistance and weight gain; in this same model TLR9 deficient mice showed less steatosis, inflammation, liver fibrosis, insulin resistance and weight gain compared to controls [55].

One of the major changes in the gut microbiota associated with obesity and high fat diets is a significant decrease in the gram-negative Bacteroidetes and a proportional increase in the gram-positive Firmicutes [18]. This change in the gut microbiota represents a major shift in the balance of the gram-negative to gram-positive bacteria that has the potential for alteration of the inflammatory activity secondary to TLR activation. In this environment TLR2 which recognizes extracellular ligands the NLRs are located intra-cellularly and have a variable N-terminal domain and a centrally located nucleotide-binding oligomerization domain (NOD) and a C-terminal leucine rich repeat region that recognizes PAMPs [45]. Within the host cytosol these NODs recognize specific microbial molecules; NOD1 recognizes iE-DAP (γ-D-glutamyl-meso-diaminopimelic acid) which contains fragments from most gram-negative and some gram-positive bacteria while NOD2 recognizes muramyl dipeptide (MDP) found in the majority of both gram-positive and gram-negative bacteria [45]. Within the N-terminal domain there is further protein modules involved in downstream signaling pathways including a caspase recruitment domain (CARD). These CARDs are particularly important as multiple NLRs can join together through an adaptor protein such as ASC (apoptosis-associated speck-like protein) to form an inflammasome which controls caspase activation and subsequent production of pro-inflammatory cytokines [45,62].

These inflammasomes and caspases play critical roles in the immune response through regulation of inflammation and also cell death. Caspase-1 activation by inflammasomes leads to the cleavage of pro-IL-1β and pro-IL-18 into their biologically active forms, causing recruitment of inflammatory cells, production of TNF-γ, and enhancement of natural killer cell activity [45]. One inflammasome in particular NLRP6 appears to have a critical role in controlling intestinal homeostasis; NLRP6 deficiency has been associated with: decreased levels of IL-18, increased concentrations of Bacteroidetes and the bacterial phylum TM7 enhanced activation of MAP kinase and NF-Kβ upon TLR ligation defective autophagy of goblet cells, impaired mucin secretion into the gut lumen and improved resistance to infection with Listeria, Salmonella, and E. coli [62–66]. As such NLRP6 may serve to dampen certain inflammatory signals by promoting bacterial dissemination and colonization of systemic organs while at the same time clearing enteric pathogens from the mucosal surface to maintain intestinal homeostasis.

In this manner inflammasome function is intrinsically related to the gut microbiota and regulation of TLR activation, which also has an important role in controlling the progression of liver injury. This has been evidenced in animal studies showing that NLRP6 and NLRP3 along with IL-18 negatively regulate progression of injury in NAFLD and NASH [64]. Further, inflammasome deficiency may lead to increased TLR4 and TLR9 agonist production into the portal circulation, thereby triggering increased inflammation and driving progression of the injury mainly through hepatic TNF-α production. A key regulator of this increased TLR4 and TLR9 agonist production may be microbiota-induced subclinical colonic inflammation through chemokine CCL5 secretion [64]. Additionally, some of the metabolic alterations in these inflammasome-deficient mice can be horizontally spread with the resulting altered gut microbiota negatively impacting NAFLD progression [64].

Proinflammatory Cytokines

Both the TLRs and the NLRs ultimately affect downstream pathways that lead to alterations in the levels of proinflammatory cytokines. Among these cytokines TNF-α and IL-1β are the major cytokines driving liver injury and progression of NAFLD. The primary role of TNF-α is in the regulation of immune cells. Disregulation of TNF production has been implicated in a variety of human diseases including a spectrum of rheumatologic diseases and inflammatory bowel disease. Animal models have also shown that TNF-α and IL-1β deficiencies confer resistance to NAFLD and NASH respectively while on a HFD [67,68].

The cytokine TNF-α is involved in a number of pathways that can ultimately affect the predisposing factors for NAFLD. Most importantly TNF-α cause increased insulin resistance through alteration of insulin receptor function and also increasing cholesterol
accumulation in hepatocytes through the inhibition of LDL receptors and efflux transporters. [12]. Increased lipid levels in these hepatocytes alter normal signaling and lead to an increase in reactive oxygen species which drives cell death signaling. In addition increased cholesterol accumulation with in hepatocytes can result in increased TLR4 through suppression of the endosomal-lysosomal degradation pathway of TLR4 [52]. In recent years researchers have been able to identify that Kupffer cells resident macrophages in the liver seem to play a crucial role in detecting DAMPs and activating inflammasome responses. Studies with human biopsies have shown an increase in increased expression of tight junction proteins. Both of these pathways leads to a more comprehensive understanding of the mechanism of prebiotics in NAFLD is an increased ratio of lipogenesis.

Rifaximin a non-absorbable antibiotic is one potential candidate for the treatment of NAFLD. Rifaximin has been shown in a number of studies to improve liver injury in patients with cirrhosis, most notably for its effects in treating hepatic encephalopathy [71-73]. Currently there is an ongoing randomized trail assessing efficacy of rifaximin in NAFLD/NASH through measurements of proinflammatory cytokine and endotoxin levels including TNF-α and TLR4 activation [74].

Given the high cost and adverse effects associated with chronic antibiotic use, however results of this study and others will be needed before rifaximine or other antibiotics can be recommended as a therapeutic option for NAFLD.

**Prebiotics**

Prebiotics were originally defined as “nondigestible food ingredients that beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria in the colon”; however they are now more loosely defined as “selectively fermented ingredients that allow specific changes both in the composition and/or activity in the gastrointestinal microflora that confer benefits.” [75-77]. In order for a food to be classified as a prebiotic it must resist gastric acidity, hydrolysis by mammalian enzymes and absorption in the upper gastrointestinal tract, such that it is able to be fermented by the gut microbiota into short-chain fatty acids (SCFAs), including acetate, propionate and butyrate, that can be used for energy [12,77]. The primary prebiotics used the two inulin-type fructans oligofructose (OFS) and fructo-oligosaccharides (FOS) and the galactan, galacto-oligosaccharides (GOS) [78,79]. The fructans are the most extensively studied prebiotics for use in metabolic syndrome with the differences between the fructans being only the number of repeating units of D-fructose in the polymer chain [78].

The role of prebiotics in the treatment of NAFLD centers largely on the functional roles of improved glucoregulation and modified lipid metabolism [78]. Specific alterations of the gut microbiota by these prebiotics include favored growth of indigenous bifidobacteria and/or lactobacilli and decreased luminal pH which impedes the growth of pathogens [78,79].

Modification of lipid metabolism by prebiotics is centered on regulation of de novo fatty acid synthesis. While healthy individuals usually have minimal hepatic de novo lipogenesis NAFLD patients with hyperinsulinemia can have up to 26% of the hepatic triglyceride content as a result of de novo lipogenesis [8]. Importantly, this increased de novo lipogenesis is also an important phenotypic factor in genetically obese mice, another clinical feature that has strong implications in the development of NAFLD in humans [80]. Prebiotics have been shown to attenuate de novo lipogenesis, likely through a mechanism of action that includes alterations in gene expression of regulatory enzymes for lipogenesis [78]. Additionally, prebiotics may decrease lipogenesis by altering the by-products of microbiota fermentation. Of the SCFA by-products, acetate and propionate are the major constituents delivered to the liver, whereas most butyrate is metabolized in the colon; in the liver, acetate promotes lipogenesis while propionate inhibits lipogenesis [81-83]. One suggested mechanism of prebiotics in NAFLD is an increased ratio of propionate to acetate, which may promote a decrease in hepatic lipogenesis.
Alteration of the gut microbiota by prebiotics may also affect the levels of proinflammatory cytokines secondary to changes in intestinal permeability and levels of LPS. Using the prebiotic (oligofructose) in mice fed a HFD gut microbiota showed an increase in the levels of Bilidobacterium, which was positively associated with decreased endotoxemia and proinflammatory cytokines as a result of decreased levels of LPS [84]. The complexity of this relationship between the gut microbiota and intestinal permeability is further highlighted as researchers have also shown decreased intestinal permeability and LPS absorption in prebiotic treated mice who have increased production of glucagon-like-peptide 2 [85].

There is currently little data from human studies concerning the use of prebiotics as it pertains to alterations in inflammation with only one randomized placebo controlled pilot study of 7 patients with NASH showing decreased levels of aminotransferases after 8 weeks; however, there is some evidence for prebiotics in lowering lipid levels improving both weight loss and insulin resistance. In eight studies using prebiotics in human subjects with diabetes or hyperlipidemia levels of cholesterol and triglycerides were shown to decrease between 6-20% and 14-27%, respectively [86]. One randomized control trail assigned patients to receive either the prebiotic oligofructose or placebo for 12 weeks and found a significant reduction in weight of 1.03 ± 0.43 kg in the prebiotic group versus a weight gain of 0.45±0.31 kg in the placebo group (P = 0.01) [87]. Additionally patients in the prebiotic group reported a decreased caloric intake that was associated with decreased ghrelin and increased peptide YY levels.

In summary prebiotics may serve a role in the modification of lipid metabolism by attenuating de novo lipogenesis and altering byproducts of microbial fermentation. Other potential benefits of prebiotics include decreased intestinal permeability and alteration of gut hormones that may lead to decreased caloric intake. While there is insufficient clinical evidence to support routine use of prebiotics in NAFLD patients the evidence from animal studies supports consideration for the use of prebiotics in select patients who may not have responded to other therapeutic options.

Probiotics

Probiotics are live microorganisms that, when administered in adequate quantities, confer a health benefit to the host [88]. Probiotics have been used in a number of disease processes, including NAFLD, in an attempt to produce a health benefit through the correction of gut dysbiosis. The use of probiotics in NAFLD is focused on the basis that many patients with NAFLD have increased intestinal permeability secondary to small intestinal bacterial overgrowth (SIBO) [11]. As discussed earlier, the increased intestinal permeability results from disruption of intercellular tight junctions and leads to increased translocation of bacterial products into the bloodstream, causing increased endotoxemia and delivery of these products to the liver activating inflammatory cytokines. There are several different mechanisms to justify a potential role for the use of probiotics in the treatment of NAFLD. First, probiotics have been shown to produce a number of antimicrobial factors which lead to a decreased pH and inhibition in the growth of pathogenic gram negative bacteria [89]. In addition, some probiotic strains can compete with and displace pathogenic bacteria from epithelial surface receptors in the gut [89]. Intestinal permeability is also improved as lactobacillus and bifidobacteria mixtures have been shown to increase mucin secretion through upregulation of the mucin producing genes MUC2 and MUC3 [89]. Overall, the activity of probiotics should lead to improvements in NAFLD by partially correcting the dysbiosis of the gut microbiota and by limiting SIBO and its resultant increased intestinal permeability and endotoxia.

The efficacy of probiotics in NAFLD animals models has been well established in a variety of Lactobacillus species, with a number of studies showing reductions in LDL, cholesterol and triglycerides along with histological improvement and amelioration of the inflammation and steatosis [89]. Despite this, there have been a limited number of human trials investigating the efficacy of probiotics in NAFLD largely related to the complex pathology of the disease and the ethical considerations required with invasive diagnostic procedures and histological sampling. To date the best clinical evidence in humans comes from a recent meta-analysis covering 134 patients from four randomized control trials receiving probiotics (including Lactobacillus, Bilidobacterium, and Streptococcus species) for the treatment of NAFLD or NASH. Results showed that compared to placebo probiotics significantly decreased ALT, AST, total cholesterol, HDL, and TNF-α; however, no significant changes in BMI, glucose or LDL were associated with probiotic use [90]. Some limitations exist when interpreting this data namely the difficulties in ascertaining changes in liver fatty infiltration as it requires a histologic specimen. Of the three studies using histologic analysis only one had post-treatment histology results. The remaining study used ultrasonography which cannot identify fatty infiltration of the liver below a threshold of 30% [90]. Lastly there remains a potential for confounding as dietary restrictions exercise and physical activity were not reported.

In summary probiotics appear to be a potential treatment option for NAFLD. Numerous studies have shown improvements in the intestinal dysbiosis leading to decreasing intestinal permeability endotoxemia and subsequent inflammation. While the majority of evidence supporting the use of probiotics is from animal studies with only a few clinical trials given the technical difficulties of performing this research in humans the positive findings from the clinical trials should be encouraging for efficacy of probiotics in NAFLD.

Bottom-line

There are number of potential therapeutic roles for antibiotics, prebiotics and probiotics in the treatment of NAFLD based on alterations of the gut microbiota. While currently there is limited evidence to support the use of antibiotics both prebiotics and probiotics have encouraging results in animal studies for improving the gut dysbiosis and potentially inducing a clinical benefit in NAFLD patients. As such clinicians should be aware of these options and consider them for patients either not responding to other treatment approaches or who desire an adjunctive treatment option.

Conclusion

The global epidemic of obesity and the increasing prevalence of type 2 diabetes has propelled NAFLD as the most common chronic non-viral liver disease. The complication of NASH in this population is formidable given the numbers of patients affected. Additionally, the burden of NAFLD on the healthcare system is expected to increase, as by 2020 this is projected to be the number one indication for liver transplantation in the US [2]. Accordingly, it is essential that clinicians understand the modifiable risk factors for NAFLD. A summary of the currently available data and our core tips are provided in Table 1.
<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Pathogenesis</th>
<th>Current Evidence</th>
<th>Core Tip</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>Increased Firmicutes/Decreased Bacteroidetes in comparison to lean counterparts</td>
<td>Suppression of Fliaf leads to increased lipopolysaccharide (LPS), thereby increasing cellular uptake of fatty acids and adipocyte triglyceride accumulation</td>
<td>Obesity is clearly a strong risk factor in the pathogenesis of NAFLD with a prevalence twice that of lean comparators. Obese patients may have a characteristic increased Firmicutes/Decreased Bacteroidetes within their gut microbiota. Further investigation into the regulation of gut hormones and the regulatory factors for lipolysis and lipogenesis will help expand our understanding of the relationship between the gut microbiota and obesity in NAFLD.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Increased SCFAs induce the release of peptide YY (PYY)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Germ-free mice fed a high-fat, high-sugar diet were resistant to development of obesity; introduction of gut flora led to increased body weight, body fat, increased hepatic lipogenesis, and fat deposition[11,16,17]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Colonization of gut with Bacteroidetes thetaotaomicron and Methanobrevibacter smithii leads to increased suppression of Fliaf and subsequent obesity [26]</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Excess Firmicutes can result in increased SCFA production, and increased calorie absorption via PYY, ultimately leading to obesity; further, excess SCFAs can be converted into triglycerides within the liver increasing hepatic steatosis [11,19,20]</td>
<td></td>
</tr>
<tr>
<td>Insulin Resistance</td>
<td>Primarily driven by inflammatory mediators and immune responses</td>
<td>Link between insulin resistance and liver inflammation through these inflammatory pathways</td>
<td>Insulin resistance affects a wide variety of biochemical pathways involved in the pathogenesis of NAFLD. In particular, it appears to incorporate both the immune responses and inflammatory changes that occur in NAFLD. Currently, specific alterations in the gut microbiota relating to insulin resistance have not been found in NAFLD due to the vast role of insulin signaling in metabolism; however, continued investigation may prove to isolate more specific gut alterations related to insulin resistance.</td>
</tr>
<tr>
<td>Immune Responses</td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>TLR9 can lead to activation of IL-1β and a subsequent increase in liver steatosis, inflammation, and fibrosis; TLR2 and TLR5 may play protective roles</td>
<td>Disruption of the normal gut microbiota can result in altered immune system activation. These immune responses affect a number of pathways related to the risk factors for NAFLD. Additionally, they can promote the progression of NAFLD to NASH through increased inflammation. Particularly important to the maintenance of gut homeostasis are the control of intestinal permeability and the levels of bacterial products, which can activate TLRs, triggering additional immune responses.</td>
</tr>
<tr>
<td></td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>NLRP6 inflammasome may be protective in the maintenance of intestinal homeostasis by clearing enteric pathogens and dampening bacterial dissemination</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>TNF-α and IL-1β are the major proinflammatory cytokines driving liver injury and progression of NAFLD ? NASH</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>Rodents on a high-fat diet (HFD) have increased inflammation through induction of TLR4, resulting in increased intestinal permeability and endothoxin levels; these changes are not reproducible in TLR deficient mice. Additionally, TLR4 deficient mice are resistant to NAFLD[46,49]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>TLR9 deficient mice have decreased steatosis, inflammation, fibrosis, insulin resistance and weight gain in comparison to controls.[55]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>TLR2 deficient mice on a HFD have disrupted tight junctions that was preserved in wild type mice given a TLR2 agonist.[47,60] TLR5 deficient mice showed obesity and steatohepatitis that was exacerbated by a HFD.[61]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>NLRP6 deficiency has been associated with decreased IL-8, increased Bacteroidetes, defective autophagy of goblet cells, impaired mucin secretin into gut lumen, and enhanced activation of MAP kinase and NF-Kβ upon TLR binding [62-66].</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>TNF-α can increase insulin resistance by altering insulin receptor function; additionally, it can increase cholesterol accumulation in hepatocytes through inhibition of LDL receptors and efflux transporters. [12]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TLR4 is activated by LPS from gram-negative bacteria and leads to inflammatory responses</td>
<td>IL-1β suppresses PPARγ, causing accumulation of triglycerides within hepatocytes and increasing expression of pro-apoptotic pathways. [12]</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Summary of NAFLD risks, pathogenesis, current evidence and core tips

The gut microbiota has long been understood to play a role in the pathogenesis of various diseases; however recent advances in technology have greatly increased our ability to analyze to composition of the gut microbiota and its alterations relative to specific diseases. Current evidence strongly supports the existence of certain characteristic changes in the gut microbiota affecting signaling pathways and immune responses which play a role in the development and progression of NAFLD. Additionally the gut microbiota may be a potential effective therapeutic target for improving outcomes associated with NAFLD.


7. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ (2014) Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146: 726-735.


54. Ye D, Li FY, Lam KS, Li H, Jia W, et al. (2012) Toll-like receptor-4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice via the TLR4 signaling pathway. JGDS, an open access journal ISSN:2161-069X JGDS, an open access journal


